Author:
Suresh Karthik,Voong Khinh Ranh,Shankar Bairavi,Forde Patrick M.,Ettinger David S.,Marrone Kristen A.,Kelly Ronan J.,Hann Christine L.,Levy Benjamin,Feliciano Josephine L.,Brahmer Julie R.,Feller-Kopman David,Lerner Andrew D.,Lee Hans,Yarmus Lonny,D’Alessio Franco,Hales Russell K.,Lin Cheng Ting,Psoter Kevin J.,Danoff Sonye K.,Naidoo Jarushka
Funder
National Heart, Lung and Blood Institute
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference19 articles.
1. Immune checkpoint inhibitors in advanced non-small cell lung cancer;Assi;Cancer,2018
2. Nivolumab and pembrolizumab for non-small cell lung cancer;Morgensztern;Clin Cancer Res,2016
3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006
4. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline;Brahmer;J Clin Oncol,2018
5. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy;Naidoo;J Clin Oncol,2017
Cited by
272 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献